Elevance Health (formerly Anthem) faces similar Medicare Advantage and Medicaid rate pressures as managed care peers but with relatively less Optum-equivalent diversification. Carelon services growth is the strategic pivot but smaller scale than Optum. Blue Cross plan portfolio provides commercial insurance stability. Medical cost trend remains the dominant near-term variable. Less politically exposed than UnitedHealth.
Thesis reviewed May 29, 2026
Elevance Health Inc. is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States82EXITView United States risk detail →🏥Healthcare33NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| CVS | CVS Health Corporation | 40 | +15% | ↓3% | AVOID |
| HCA | HCA Healthcare Inc. | 40 | +9% | ↓3% | EARLY |
| UNH | UnitedHealth Group Inc. | 37 | +16% | ↓3% | AVOID |
| TMO | Thermo Fisher Scientific Inc. | 37 | +11% | ↓3% | EARLY |
| CI | The Cigna Group | 37 | +9% | ↓3% | NEUTRAL |
| ELV | Elevance Health Inc. | 37 | +7% | ↓3% | NEUTRAL |
| TEVA | Teva Pharmaceutical Industries Ltd. | 37 | +9% | ↓3% | NEUTRAL |
Investors who hold ELV may also have indirect exposure through these country funds.
Elevance MLR runs higher than guidance on Medicaid utilization
Carelon services revenue growth +20%, scale build continues
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Alan Armstrong | Buy | $1k–$15k | Mar 27, 26 | ||
| Markwayne Mullin | Buy | $15k–$50k | Dec 29, 25 | +5.5% | |
| Jared MoskowitzFL | D | Buy | $1k–$15k | Nov 8, 24 | +1.9% |
| John JamesMI | R | Buy | $1k–$15k | Sep 4, 24 | -25.1% |
| John JamesMI | R | Buy | $1k–$15k | Nov 10, 23 | -27.1% |
| John JamesMI | R | Buy | $1k–$15k | Nov 16, 23 | -27.1% |
| Jared MoskowitzFL | D | Buy | $1k–$15k | Feb 13, 24 | -25.1% |
| Jared MoskowitzFL | D | Buy | $1k–$15k | Feb 1, 24 | -22.4% |
| Jared MoskowitzFL | D | Buy | $1k–$15k | Jul 1, 24 | -22.4% |
| Jared MoskowitzFL | D | Buy | $1k–$15k | Jul 5, 24 | -22.4% |